Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Plasma-Powered gel could speed up healing of chronic wounds

NCT ID NCT07541196

Disease control Sponsor: Benjamín Gonzalo Rodríguez Méndez Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new hydrogel made with plasma-activated water on chronic wounds like diabetic foot ulcers and pressure sores. Fifty adults will either get the gel or standard wound care for 12 weeks. Researchers will check if the gel helps wounds close faster and lowers bacteria.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hydrogel made with plasma-activated water (PAW)
What this could lead to
If it works, this could offer a new, affordable way to help chronic wounds heal faster and reduce infection risk.
What could go wrong
This is a small, early-stage trial with only 50 people. The hydrogel may not work better than standard care, and results may not apply to all wound types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults ≥ 18 years of age. * Diagnosis of chronic wound (diabetic foot ulcer Wagner grade 1-2, pressure injury grade I-III, dehiscent surgical wound, venous or arterial ulcer) with duration \> 3 months. * Wound surface area between 2 cm² and 20 cm². * For diabetic patients: HbA1c \< 9% (stable metabolic control). * Able and willing to provide written informed consent. Exclusion Criteria: * Clinical or radiological evidence of osteomyelitis (Wagner grade \> 3). * Severe arterial insufficiency (ankle-brachial index \< 0.5). * Use of systemic corticosteroids or immunosuppressants. * Pregnancy or lactation. * Known autoimmune skin disease (e.g., pemphigus, epidermolysis bullosa). * Active malignancy or undergoing chemotherapy/radiotherapy. * Participation in another interventional clinical trial within 30 days prior to screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arterial ulcer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic ulcer of skin decubitus ulcer Diabetic Foot ulcer of lower limbs Varicose Ulcer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arterial ulcer Chronic wound Diabetic foot ulcer (DFU) Pressure ulcer (PU) Venous leg ulcer Wound dehiscence

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Plasma Physics Laboratory, National Institute of Nuclear Research

    RECRUITING

    Ocoyoacac, State of Mexico, 52750, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.